Kyushu University Academic Staff Educational and Research Activities Database
List of Presentations
Masatoshi Eto Last modified date:2020.07.14

Professor / Department of Urology, Graduate School of Medical Sciences / Department of Clinical Medicine / Faculty of Medical Sciences


Presentations
1. Ueda S, Irie A, Senju S, Eto M,Nishimura Y, Effective combination immunotherapy for chemoresistant mouse bladder cancer using peptide vaccines and PD-1 blockade., 第48回日本免疫学会学術集会, 2019.12.
2. 上田翔平、入江 厚、千住 覚、江藤正俊、西村泰治, Effective combination immunotherapy for chemoresistant mouse bladder cancer using peptide vaccines and PD-1 blockade., 第71回西日本泌尿器科学会総会, 2019.11.
3. 小林 聡、Jeung D、Cho B、牟田口 淳、Jung K、武内在雄、塩田真己、猪口淳一、立神勝則、橋爪 誠、Hong J、江藤正俊, Development of next-generation surgical navigation system in Robot-assisted partial nephrectomy., 第71回西日本泌尿器科学会総会, 2019.11.
4. Eto M, A novel navigation system in robot-assisted partial nephrectomy., 2019 KUA Annual Meeting, 2019.11.
5. Imada K, Kashiwagi E, Monji K, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, Can preoperative CT findings predict the pathological outcome of robot-assisted radical prostatectomy?, 39th Congress of the Société Internationale d’Urologie, 2019.10.
6. Eto M, Urological Association of Asian Symposium session;
UAA: Cancer, 39th Congress of the Société Internationale d’Urologie, 2019.10.
7. Monji K, Imada K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, Nivolumab treatment for patients with metastatic renal cell carcinoma: A retrospective analysis in Kyushu University Hospital., The 36th KOREA-JAPAN Urological Congress, 2019.09.
8. Eto M, Precision Medicine in Pharmacotherapy for Prostate Cancer Using Genetic Polymorphism., The 36th KOREA-JAPAN Urological Congress, 2019.09.
9. Eto M, The role of surgery in the treatment of metastatic kidney cancer., The East Asia Urological Oncology Society 2019, 2019.09.
10. Masaoka H, Ito H, Matsuo K, Eto M, 5-year relative survival rates among men aged ≥80 years with prostate cancer in Japan: potential overtreatment for localized cancer., 17th Urological Association of Asia Congress, 2019.08.
11. Monji K, Inokuchi J, Imada K, Kashiwagi E,Takeuchi A, Shiota M, Tatsugami K, Eto M, Impact of preoperative ureteroscopy on intravesical recurrence in patients after nephroureterectomy in Kyushu University Hospital., 17th Urological Association of Asia Congress, 2019.08.
12. Kashiwagi E, Shiota M, Imada K, Monji K, Takeuchi A, Inokuchi J, Tatsugami K, Eto M. , Relationship between body composition and hormone sensitivity for androgen deprivation therapy in metastatic prostate cancer patients., 2019 ASCO 55nd Annual Meeting, 2019.06.
13. Shiota M, Onozawa M, Hinotsu S, Eto M, Naito S, Akaza A; Japan Study Group of Prostate Cancer (J-CaP), Family history in primary hormone therapy for prostate cancer from a community-based multi-institutional Japan-wide database., 2019 ASCO 55nd Annual Meeting, 2019.06.
14. Umezu D, Okada N, Sakoda Y, Adachi K, Eto M, Tamada K, Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment., 34st Annual EAU Congress 2019, 2019.03.
15. Kashiwagi E, Imada K, Shiota M, Takeuchi A, Inokuchi J, Tatsugami K, Eto M, Thick perirenal fat predicts the growth pattern of renal cell carcinoma., 2019 Genitourinary Cancers Symposium(ASCO-GU), 2019.02.
16. Inokuchi J, Kuroiwa K, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanikawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Ito K, Mizusawa J, Eba J, Naito S, The Urologic Oncology Study Group of Japan Clinical Oncology Group (JCOG), The role of adjuvant chemotherapy for pT2-4 upper urinary tract urothelial cancer: Exploratory analysis of large multi-institutional study (JCOG1110A)., 2019 Genitourinary Cancers Symposium(ASCO-GU), 2019.02.
17. Eto M, Current status and future perspectives of molecular targeted therapy against kidney cancer., The 35th KOREA-JAPAN Urological Congress, 2018.12.
18. Monji K, Inokuchi J, Imada K, Kashiwagi K, Takeuchi A, Shiota M, Tatsugami K, Eto M, Impact of preoperative ureteroscopy on intravesical recurrence in patients after nephroureterectomy in Kyushu University Hospital., The 35th KOREA-JAPAN Urological Congress, 2018.12.
19. 牧 知子、梶岡俊一、波止 亮、今田憲二郎、江藤正俊, Elucidation of the novel alternative relaxation mechanism of Mirabegron in detrusor smooth muscle not via β3 adrenoceptor., 第70回西日本泌尿器科学会総会, 2018.11.
20. Namitome R, Imada K, Maki T, Kajioka S, Eto M, Lower Urinary Tract Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorder., 38th Congress of the Société Internationale d’Urologie, 2018.10.
21. Imada K, Kiyoshima K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, Analysis of Bacillus Calmette-Guérin (BCG) therapy for the patients with urothelial carcinoma of the prostatic urethra., 38th Congress of the Société Internationale d’Urologie, 2018.10.
22. Masaoka H, Matsuo K, Eto M, Effect of Polymorphisms in Alcohol-Metabolizing Enzymes on Bladder Cancer Risk Associated with Drinking Alcohol., 38th Congress of the Société Internationale d’Urologie, 2018.10.
23. Eto M, Current Status and Future Perspectives regarding Biomarkers for Renal Cell Carcinoma., 38th Congress of the Société Internationale d’Urologie, 2018.10.
24. Kobayashi S, Cho B, Tatsugami K, Huaulmé A, Jannin P, Hasizume M, Eto M, Surgical Navigation in robot-assisted partial nephrectomy improve operative duration and surgical skills., 36th World Congress of Endourology (WCE2018), 2018.09.
25. Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M, Missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer., 2018 ASCO 54nd Annual Meeting, 2018.06.
26. Matsumoto T, Uchiumi T, Shiota M, Imada K, Dejima T, Kashiwagi E, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M, Targeting mitochondrial oxidative phosphorylation induces apoptosis via ER stress selectively to CD44v9 positive cells with cancer stem cell-like properties: importance of plasticity., The 113th Annual Meeting AUA 2018, 2018.05.
27. Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, The important role of glycine N-methyltransferase in the proliferation of renal and urothelial carcinoma., The 113th Annual Meeting AUA 2018, 2018.05.
28. Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, SEMA3C drives cancer growth and treatment resistance via cognate ligand-independent activation., The 113th Annual Meeting AUA 2018, 2018.05.
29. Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Regional distribution of lymph node metastasis in upper urinary tract urothelial cancer, sub-analysisof large multi-institutional study (JCOG1110A)., 第106回日本泌尿器科学会総会, 2018.04.
30. Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M, Independent validation of missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer., 16th Urological Association of Asia Congress, 2018.04.
31. Inokuchi J, Kuroiwa K, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanikawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, et al., Regional distribution of lymph node metastasis in upper urinary tract urothelial cancer, sub-analysis of large multi-institutional study (JCOG1110A)., 33st Annual EAU Congress 2018, 2018.03.
32. Takeuchi A, Shiota M, Kamiryo Y, Tatsugami K, Eto M, Rationale and possibility of intravesical Bacillus Calmette-Guerin therapy with cytokine against bladder cancer., 33st Annual EAU Congress 2018, 2018.03.
33. Takeuchi A, Shiota M, Gleave ME, Ong CJ, Eto M, Combinational therapeutics targeting Semaphorin 3C with anticancer drugs in prostate cancer., 33st Annual EAU Congress 2018, 2018.03.
34. Dejima T, Takeuchi A, Leong J, Tam K, Tombe T, Erho N, Black PC, Eto M, Gleave ME, Ong CJ, LIM-SH3 domain protein 1 promotes tumorgenesis in prostate cancer., 33st Annual EAU Congress 2018, 2018.03.
35. Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M, Independent validation of missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer., 2018 Genitourinary Cancers Symposium(ASCO-GU), 2019.06.
36. Masatoshi Eto, [Renal Cancer]
Update in the Treatment of mRCC, How to Use Immune Checkpoint Blockade., Advancements in Urology 2017: An AUA/JUA Symposium, 2017.01.
37. Masatoshi Eto, Molecular Medicine: Shaping the Future/ Kidney Cancer., 36th Congress of the Société Internationale d’Urologie, 2016.10.
38. Masatoshi Eto, Urology in Asia Symposium
SessionⅡ:Kidney, Ureter, Bladder, Penile Cancer., 36th Congress of the Société Internationale d’Urologie, 2016.10.
39. Masatoshi Eto, Current Status and Future Perspective of Medical Treatment for RCC., 35th Congress of the Société Internationale d'Urologie, 2015.10.
40. Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Naito S, Renal cancer treatment with recipient Iymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation., 30th Annual EAU Congress 2015, 2015.03.